Cathie Wood’s ARK Invest has trimmed its exposure to Palantir (NASDAQ: PLTR) stock, one of the biggest AI winners of the year, even as the equity continues its extraordinary run.
According to ARK’s latest trade disclosure for October 27, 2025, the fund sold 13,922 shares of Palantir from the ARK Fintech Innovation ETF (ARKF), marking a rare profit-taking move on a stock that has surged more than 150% year to date and recently reached an all-time high of $190.84. The stock ended the Monday trading session at $189.
PLTR YTD stock price chart. Source: FinboldPalantir’s rally has been fueled by strong fundamentals and growing investor enthusiasm for its expanding role in artificial intelligence and government data analytics.
The company’s latest financials point to its strength, with gross profit margins near 80% and revenue growth of 39% over the past year. Despite trading above its fair value, Palantir remains a market favorite as analysts continue to raise earnings forecasts.
Beyond its stock performance, Palantir is deepening its presence across the AI and defense technology landscape. Its software was recently used in Red Cat Holdings’ Black Widow drone tests for the U.S. Army, while new partnerships with Lumen Technologies and Snowflake aim to accelerate enterprise adoption of Palantir’s Foundry platform.
Cathie Wood portfolio update
While trimming Palantir, Wood’s ARK funds were net buyers overall. The firm increased positions in Block (NYSE: SQ), Intellia Therapeutics (NASDAQ: NTLA), 10x Genomics (NASDAQ: TXG), and Pacific Biosciences (NASDAQ: PACB), all key holdings in ARK’s genomics and innovation portfolios.
The funds were also added to DraftKings (NASDAQ: DKNG), Amazon (NASDAQ: AMZN), Alibaba (NYSE: BABA), and DoorDash (NASDAQ: DASH), reflecting continued confidence in digital commerce and biotech.
Meanwhile, ARK reduced positions in several other high-growth names alongside Palantir, including Shopify (NYSE: SHOP), Roblox (NYSE: RBLX), Iridium Communications (NASDAQ: IRDM), SoFi Technologies (NASDAQ: SOFI), and Ionis Pharmaceuticals (NASDAQ: IONS).
The mixed trades highlight Wood’s ongoing strategy of rebalancing amid a volatile but rewarding year for innovation-focused stocks.
Featured image from Shutterstock
Source: https://finbold.com/cathie-wood-offloads-this-ai-stock-despite-150-rally-in-2025/
